

**CURRICULUM VITAE
FRANCESCA BONELLO**

CURRENT AFFILIATION: Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy

EDUCATION

- Faculty of Medicine, Università degli Studi di Torino, Italy, in the years 2010-2016

Medical degree: 22/07/2016

110/110 Lode, Dignità di Stampa e Menzione d'Onore.

With the dissertation: "Open label phase I/II study of carfilzomib, pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma patients"

- Member of "Ordine dei Medici della Provincia di Torino" from 27/02/2017

UNDERGRADUATE MEDICAL TRAINING:

- Clinical clerkship

Clinical Immunology , August 2015

Hospital Universitario Gaffrè e Guinlè, Rio de Janeiro (BR)

GRADUATE MEDICAL TRAINING

- Residency: Hematology, December 2017- ongoing

A.O.U Città della Salute e della Scienza di Torino , Italy

CERTIFICATIONS:

- DAN BLS-D (adult/pediatric care) provider, 20/12/2016

FOREIGN LANGUAGES:

	WRITING	SPEAKING	READING
English	excellent	excellent	excellent
Portoguese	good	good	very good

Language certification: Cambridge English CAE, 2009. Council of Europe Level C1.

PUBLICATIONS:

- Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins. Leuk Lymphoma. 2016;57(3):537-56.

- Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma. *Expert Rev Anticancer Ther.* 2017 Jan;17(1):75-87
- How is patient care for multiple myeloma advancing? *Expert Rev Haematol.* 2017 Jun;10(6) 551-561
- Determining treatment intensity in elderly patients with multiple myeloma. *Expert Rev Anticancer Ther.* 2018;18(9):917-930. doi:10.1080/14737140.2018.1496823
- CD38 as an immunotherapeutic target in multiple myeloma. *Expert Opin Biol Ther.* 2018;18(12):1209-1221. doi:10.1080/14712598.2018.1544240 (First name)
- Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study Blood 2015, ASH abstract.
- A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients Blood 2016, ASH abstract.
- Doublet vs triplet lenalidomide-containing regimens followed by maintenance: subgroup analysis by frailty status after a median follow-up of 5 years (EMN01 phase III study). EHA Library. Jun 16 2018; PS1293

Turin, October 10th, 2019
 Francesca Bonello, M.D